ASLAN Pharmaceuticals (NASDAQ:ASLN) Stock Rating Reaffirmed by HC Wainwright

ASLAN Pharmaceuticals (NASDAQ:ASLNGet Rating)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Thursday, TipRanks reports. They presently have a $8.00 price target on the stock.

Separately, Piper Sandler lowered their price objective on ASLAN Pharmaceuticals from $8.00 to $3.00 and set an “overweight” rating for the company in a research report on Monday, May 23rd.

ASLN stock traded up $0.05 during trading on Thursday, hitting $0.51. The stock had a trading volume of 4,118 shares, compared to its average volume of 362,235. The stock has a market cap of $35.43 million, a price-to-earnings ratio of -0.92 and a beta of 2.36. The company has a debt-to-equity ratio of 0.81, a quick ratio of 9.63 and a current ratio of 9.63. The company’s 50 day moving average price is $0.51 and its two-hundred day moving average price is $0.82. ASLAN Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $3.81.

ASLAN Pharmaceuticals (NASDAQ:ASLNGet Rating) last issued its quarterly earnings results on Wednesday, April 27th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). As a group, sell-side analysts forecast that ASLAN Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Waterfront Wealth Inc. purchased a new stake in ASLAN Pharmaceuticals during the fourth quarter valued at about $302,000. Millennium Management LLC grew its holdings in shares of ASLAN Pharmaceuticals by 8.8% during the 3rd quarter. Millennium Management LLC now owns 1,468,207 shares of the company’s stock worth $2,613,000 after purchasing an additional 118,919 shares during the period. GSA Capital Partners LLP acquired a new stake in ASLAN Pharmaceuticals during the 4th quarter worth approximately $89,000. Renaissance Technologies LLC purchased a new position in ASLAN Pharmaceuticals in the first quarter valued at approximately $64,000. Finally, Bank of America Corp DE lifted its position in ASLAN Pharmaceuticals by 34.4% during the first quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock valued at $233,000 after buying an additional 66,544 shares in the last quarter. 38.65% of the stock is currently owned by institutional investors and hedge funds.

ASLAN Pharmaceuticals Company Profile (Get Rating)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.

See Also

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.